Navigation Links
Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
Date:10/21/2011

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at KV Pharmaceutical Company (NYSE: KV-A, KV-B).

(Logo: http://photos.prnewswire.com/prnh/20111014/MM87207LOGO)

Robbins Umeda LLP's investigation focuses on whether officials at KV Pharmaceuticals breached their fiduciary duties to shareholders, maintained woefully inadequate controls, and wasted corporate assets to the detriment of the company and investors.  In particular, the firm is investigating allegations that officials at the company caused KV Pharmaceuticals to misrepresent the extent of expanded patent access granted by the U.S. Food and Drug Administration (the "FDA") for its Makena product line.  After gaining FDA approval, officials at the company made the decision to increase the price of Makena by over 1490% to $1,500.  

On March 17, 2011, two United Stated Senators sent a letter to the Federal Trade Commission stating that "KV Pharmaceuticals actions will result in diminished access to appropriate healthcare for women and result in increased preterm birth." Additionally, on March 30, 2011, the FDA issued a statement that it would not take enforcement action against companies that manufactured compound or generic versions of Makena.

Since these facts have emerged, KV Pharmaceuticals has been forced to lower the price of its Makena product line.  In addition, the company is increasingly the subject of costly public and legal scrutiny.  These events have apparently taken its toll on KV Pharmaceutical's stock price.  After recently trading as high as $13.07 per share on March 8, 2011, shares of KV Pharmaceuticals closed on October 19, 2011, at just $1.39 per share.  

If you own shares of KV Pharmaceuticals and would like more information about your rights, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or via the shareholder information form on our website.  

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/kv-pharmaceuticals/

Attorney Advertising.


'/>"/>
SOURCE Robbins Umeda LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Robbins & Myers Announces Regular Quarterly Cash Dividend
2. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
3. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
4. Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Present at KeyBanc Capital Markets Conference
7. Robbins & Myers to Present at Bairds 2010 Industrial Conference November 9, 2010
8. Robbins Geller Rudman & Dowd LLP Announces Notice of Hearing to Determine Approval of Proposed Settlement of Class Action
9. Robbins & Myers to Release Financial Results for Second Quarter Fiscal 2011
10. Robbins & Myers Completes Sale of Romaco Businesses
11. Robbins & Myers Announces Regular Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... 2016   Genomic Health, Inc. (Nasdaq: GHDX ) ... year ended December 31, 2015. --> ... 2015, compared with $69.1 million in the fourth quarter of 2014, ... increased 9 percent compared with the same period in the prior ... was $63.9 million in the fourth quarter of 2015, an increase ...
Breaking Medicine Technology:
(Date:2/11/2016)... D.C. (PRWEB) , ... February 11, 2016 , ... ... will be exhibiting at the American Academy of Dermatology Annual Meeting at the ... USA's goal is to raise awareness for both the condition of hyperhidrosis (excessive ...
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... was held in San Diego, CA, on February 6th & 7th, 2016 according to ... for those who were not invited to the NFL’s combine in Indianapolis,” says Husted. ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on ... before signing a contract and how to spot an incompetent or dishonest IT person ... e-mail and technology, it’s more important than ever to make sure the company you ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual ... Imaging Congress (WMIC), will be held in New York City, NY on September ... Therapy.” The congress will highlight and emphasize how imaging reveals a greater understanding ...
Breaking Medicine News(10 mins):